carried out

(Adnkronos) – LAUSANNE, Switzerland, March 22, 2023 /PRNewswire/ — Debiopharm (www.debiopharm.com), a Swiss-based, global biopharmaceutical company, aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the first patient dosed of their first-in-human, phase 1/2 study, GaLuCi™.